Literature DB >> 8543997

In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine.

M Bergström1, B Eriksson, K Oberg, A Sundin, H Ahlström, K J Lindner, P Bjurling, B Långström.   

Abstract

METHODS: We used PET to characterize the uptake and decarboxylation of 11C-L-DOPA in vivo in two patients with endocrine pancreatic tumors: one glucagonoma and one gastrinoma.
RESULTS: With L-DOPA labeled with 11C in the beta position, in which the radioactive label follows the molecule through decarboxylation to dopamine, significant uptake was observed in the tumors. With L-DOPA labeled in the carboxyl group, in which the label is rapidly eliminated from the tissue as 11CO2 if decarboxylation takes place, an almost complete lack of uptake is noted.
CONCLUSION: This study shows that, using selective position labeling, an in vivo action of enzymatic activity can be observed with PET and that significant decarboxylation occurs in the tested endocrine pancreatic tumors. Also, marked retention of radioactivity occurs after treatment with somatostatin analogs. It is hypothesized that this is a reflection of a reduction of exocytosis which is induced by this treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543997

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

1.  Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.

Authors:  H Orlefors; A Sundin; L Lu; K Oberg; B Långström; B Eriksson; M Bergström
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-24       Impact factor: 9.236

Review 2.  Exploring Metabolism In Vivo Using Endogenous 11C Metabolic Tracers.

Authors:  Kiel Neumann; Robert Flavell; David M Wilson
Journal:  Semin Nucl Med       Date:  2017-07-11       Impact factor: 4.446

Review 3.  From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application.

Authors:  Aleksandra Pekošak; Ulrike Filp; Alex J Poot; Albert D Windhorst
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 4.  Imaging of pheochromocytoma and paraganglioma.

Authors:  I Brink; S Hoegerle; J Klisch; T A Bley
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.

Authors:  Alexander Kroiss; Daniel Putzer; Andreas Frech; Clemens Decristoforo; Christian Uprimny; Rudolf Wolfgang Gasser; Barry Lynn Shulkin; Christoph Url; Gerlig Widmann; Rupert Prommegger; Georg Mathias Sprinzl; Gustav Fraedrich; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

Review 6.  Functional imaging of neuroendocrine tumours with PET.

Authors:  Felix M Mottaghy; Sven N Reske
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

7.  Combined PET/CT by 18F-FDOPA, 18F-FDA, 18F-FDG, and MRI correlation on a patient with Carney triad.

Authors:  Georgios Z Papadakis; Nicholas J Patronas; Clara C Chen; J Aidan Carney; Constantine A Stratakis
Journal:  Clin Nucl Med       Date:  2015-01       Impact factor: 7.794

Review 8.  Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.

Authors:  Giorgio Treglia; Fabrizio Cocciolillo; Chiara de Waure; Francesco Di Nardo; Maria Rosaria Gualano; Paola Castaldi; Vittoria Rufini; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-23       Impact factor: 9.236

9.  Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Authors:  Thierry Jacob; Dany Grahek; Nassima Younsi; Khaldoun Kerrou; Nicolas Aide; Françoise Montravers; Sonia Balogova; Cecile Colombet; Virginie De Beco; Jean N Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-10       Impact factor: 9.236

Review 10.  18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.

Authors:  Sona Balogova; Jean-Noël Talbot; Valérie Nataf; Laure Michaud; Virginie Huchet; Khaldoun Kerrou; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.